Catherine F Siengsukon1, Mohammed Alshehri2, Cierra Williams2, Michelle Drerup3, Sharon Lynch4. 1. Department of Physical Therapy and Rehabilitation Science, University of Kansas Medical Center, Kansas City, KS, United States. Electronic address: csiengsukon@kumc.edu. 2. Department of Physical Therapy and Rehabilitation Science, University of Kansas Medical Center, Kansas City, KS, United States. 3. Sleep Disorders Clinic, Cleveland Clinic, Cleveland, OH, United States. 4. Department of Neurology, University of Kansas Medical Center, Kansas City, KS, United States.
Abstract
BACKGROUND: At least 40% of individuals with multiple sclerosis (MS) exercise chronic insomnia, and the prevalence is likely higher due to underdiagnosis. Poor sleep quality has been associated with increased fatigue, anxiety, depression, and risk of relapse in individuals with MS. While cognitive behavioral therapy for insomnia (CBT-I) is the recommended treatment for chronic insomnia, the treatment effect of CBT-I in people with MS is unclear. OBJECTIVE: This pilot randomized control trial (RCT) assessed the feasibility and treatment effect of CBT-I to improve sleep quality and fatigue in individuals with MS with symptoms of insomnia. METHODS:Thirty-three individuals with MS (30 females, 3 males; 30 relapsing-remitting; 3 secondary-progressive; 53.0 ± 9.4 years old) with symptoms of insomnia were randomized into one of three arms: 1. 6-week CBT-I program, 2. 6-week active control, or 3. Single session of sleep education. Participants completed surveys to assess sleep quality, fatigue, sleep self-efficacy, depression, and anxiety. RESULTS:CBT-I in individuals with MS is feasible with high retention and adherence rate. All groups experienced a large magnitude of improvement in insomnia symptoms. The CBT-I and brief education groups experienced a large magnitude of improvement in sleep quality and fatigue. Only the CBT-I group demonstrated a large magnitude of improvement in sleep self-efficacy and depression. CONCLUSION: This is the first study to prospectively demonstrates that CBT-I is feasible in people with MS and produces promising improvements in insomnia severity, sleep quality, sleep self-efficacy and comorbid symptoms of fatigue, depression, and anxiety. Future studies are needed to determine mechanisms for these improvements and expand the scope of individuals with MS who may benefit from CBT-I. Furthermore, considering the moderate to large improvements experienced by the brief education group and the limited number of CBT-I providers, a stepped-care approach warrants consideration.
RCT Entities:
BACKGROUND: At least 40% of individuals with multiple sclerosis (MS) exercise chronic insomnia, and the prevalence is likely higher due to underdiagnosis. Poor sleep quality has been associated with increased fatigue, anxiety, depression, and risk of relapse in individuals with MS. While cognitive behavioral therapy for insomnia (CBT-I) is the recommended treatment for chronic insomnia, the treatment effect of CBT-I in people with MS is unclear. OBJECTIVE: This pilot randomized control trial (RCT) assessed the feasibility and treatment effect of CBT-I to improve sleep quality and fatigue in individuals with MS with symptoms of insomnia. METHODS: Thirty-three individuals with MS (30 females, 3 males; 30 relapsing-remitting; 3 secondary-progressive; 53.0 ± 9.4 years old) with symptoms of insomnia were randomized into one of three arms: 1. 6-week CBT-I program, 2. 6-week active control, or 3. Single session of sleep education. Participants completed surveys to assess sleep quality, fatigue, sleep self-efficacy, depression, and anxiety. RESULTS:CBT-I in individuals with MS is feasible with high retention and adherence rate. All groups experienced a large magnitude of improvement in insomnia symptoms. The CBT-I and brief education groups experienced a large magnitude of improvement in sleep quality and fatigue. Only the CBT-I group demonstrated a large magnitude of improvement in sleep self-efficacy and depression. CONCLUSION: This is the first study to prospectively demonstrates that CBT-I is feasible in people with MS and produces promising improvements in insomnia severity, sleep quality, sleep self-efficacy and comorbid symptoms of fatigue, depression, and anxiety. Future studies are needed to determine mechanisms for these improvements and expand the scope of individuals with MS who may benefit from CBT-I. Furthermore, considering the moderate to large improvements experienced by the brief education group and the limited number of CBT-I providers, a stepped-care approach warrants consideration.
Authors: Bonnie I Glanz; Irene R Dégano; David J Rintell; Tanuja Chitnis; Howard L Weiner; Brian C Healy Journal: Value Health Date: 2012-10-25 Impact factor: 5.725
Authors: James M Trauer; Mary Y Qian; Joseph S Doyle; Shantha M W Rajaratnam; David Cunnington Journal: Ann Intern Med Date: 2015-08-04 Impact factor: 25.391
Authors: Jamie S Myers; Catherine Siengsukon; Joseph Sherman; Xinglei Shen; Lauren T Ptomey; Robert Montgomery; Karen Bock; Anna Rice; William P Parker; Sally Maliski Journal: Cancer Nurs Date: 2022-04-20 Impact factor: 2.760
Authors: James F Sumowski; Sam Horng; Rachel Brandstadter; Stephen Krieger; Victoria M Leavitt; Ilana Katz Sand; Michelle Fabian; Sylvia Klineova; Robin Graney; Claire S Riley; Fred D Lublin; Aaron E Miller; Andrew W Varga Journal: Ann Clin Transl Neurol Date: 2021-05-05 Impact factor: 4.511
Authors: Jessica K Salwen-Deremer; Michael T Smith; Kelly A Aschbrenner; Hannah G Haskell; Brittany C Speed; Corey A Siegel Journal: BMJ Open Gastroenterol Date: 2021-12
Authors: Alexandria Muench; Ivan Vargas; Michael A Grandner; Jason G Ellis; Donn Posner; Célyne H Bastien; Sean Pa Drummond; Michael L Perlis Journal: Fac Rev Date: 2022-02-01
Authors: Xinyi Li; Hongying Liu; Ming Kuang; Haijiang Li; Wen He; Junlong Luo Journal: Int J Environ Res Public Health Date: 2022-08-03 Impact factor: 4.614